Testing VAS-101 for sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This early-phase trial tests a new drug called VAS-101 for people with sickle cell disease. It aims to find a safe dose and see how the drug affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a confirmed diagnosis of sickle cell disease (like HbSS, HbSC, HbSβ⁺, or HbSβ⁰).
- You have not had a blood transfusion in the last 60 days.
- You have not had a sickle cell pain crisis needing treatment in the last 14 days, and you have had fewer than three such crises in the past year.
- Your liver and kidney function tests are within certain limits, and your hemoglobin level is at least 7 g/dL.
- If you take hydroxyurea, L-glutamine, or crizanlizumab, your dose has been stable for at least 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how major organs like the brain, kidneys, heart, and liver are affected in adults with sickle cell disease, whether they've had a bone marrow transplant or gene therapy, or are continuing regular treatment. You'll get detailed tests that can help doctors understand the disease better, which may lead to improved care.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests a new treatment called BRL-101 for people with severe sickle cell disease. The treatment uses your own stem cells, which are modified in the lab and then given back to you. It aims to reduce pain crises and improve your quality of life.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
Hear when a new Sickle Cell Disease, Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.